| Gastric cancer E Van Cutsem, X Sagaert, B Topal, K Haustermans, H Prenen The Lancet 388 (10060), 2654-2664, 2016 | 1904 | 2016 |
| Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously … E Van Cutsem, J Tabernero, R Lakomy, H Prenen, J Prausová, ... J Clin Oncol 30 (28), 3499-3506, 2012 | 1660 | 2012 |
| Randomized trial of TAS-102 for refractory metastatic colorectal cancer RJ Mayer, E Van Cutsem, A Falcone, T Yoshino, R Garcia-Carbonero, ... New England Journal of Medicine 372 (20), 1909-1919, 2015 | 1384 | 2015 |
| Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants M Debiec-Rychter, J Cools, H Dumez, R Sciot, M Stul, N Mentens, ... Gastroenterology 128 (2), 270-279, 2005 | 580 | 2005 |
| MET is required for the recruitment of anti-tumoural neutrophils V Finisguerra, G Di Conza, M Di Matteo, J Serneels, S Costa, ... Nature 522 (7556), 349-353, 2015 | 435 | 2015 |
| Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials A Drilon, S Siena, R Dziadziuszko, F Barlesi, MG Krebs, AT Shaw, ... The Lancet Oncology 21 (2), 261-270, 2020 | 404 | 2020 |
| Macrophage metabolism controls tumor blood vessel morphogenesis and metastasis M Wenes, M Shang, M Di Matteo, J Goveia, R Martín-Pérez, J Serneels, ... Cell metabolism 24 (5), 701-715, 2016 | 403 | 2016 |
| PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer H Prenen, J De Schutter, B Jacobs, W De Roock, B Biesmans, B Claes, ... Clinical cancer research 15 (9), 3184-3188, 2009 | 359 | 2009 |
| Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate H Prenen, J Cools, N Mentens, C Folens, R Sciot, P Schöffski, ... Clinical Cancer Research 12 (8), 2622-2627, 2006 | 355 | 2006 |
| Molecular genetics of colorectal cancer J Bogaert, H Prenen Annals of gastroenterology 27 (1), 9, 2014 | 325 | 2014 |
| The potential and controversy of targeting STAT family members in cancer Y Verhoeven, S Tilborghs, J Jacobs, J De Waele, D Quatannens, ... Seminars in cancer biology 60, 41-56, 2020 | 277 | 2020 |
| Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients O Maertens, H Prenen, M Debiec-Rychter, A Wozniak, R Sciot, P Pauwels, ... Human molecular genetics 15 (6), 1015-1023, 2006 | 276 | 2006 |
| Common variants at the MHC locus and at chromosome 16q24. 1 predispose to Barrett's esophagus Esophageal Adenocarcinoma Genetics Consortium, ... Nature genetics 44 (10), 1131-1136, 2012 | 206 | 2012 |
| The impact of frailty on postoperative outcomes in individuals aged 65 and over undergoing elective surgery for colorectal cancer: a systematic review K Fagard, S Leonard, M Deschodt, E Devriendt, A Wolthuis, H Prenen, ... Journal of geriatric oncology 7 (6), 479-491, 2016 | 201 | 2016 |
| Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial MG Fakih, S Kopetz, Y Kuboki, TW Kim, PN Munster, JC Krauss, ... The Lancet Oncology 23 (1), 115-124, 2022 | 175 | 2022 |
| Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis P Gharahkhani, RC Fitzgerald, TL Vaughan, C Palles, I Gockel, ... The lancet oncology 17 (10), 1363-1373, 2016 | 175 | 2016 |
| Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib ER Gardner, H Burger, RH van Schaik, AT van Oosterom, EA de Bruijn, ... Clinical Pharmacology & Therapeutics 80 (2), 192-201, 2006 | 170 | 2006 |
| Podoplanin-expressing macrophages promote lymphangiogenesis and lymphoinvasion in breast cancer P Bieniasz-Krzywiec, R Martín-Pérez, M Ehling, M García-Caballero, ... Cell metabolism 30 (5), 917-936. e10, 2019 | 166 | 2019 |
| BOB CAT: a large-scale review and Delphi consensus for management of Barrett’s esophagus with no dysplasia, indefinite for, or low-grade dysplasia C Bennett, P Moayyedi, DA Corley, J DeCaestecker, Y Falck-Ytter, G Falk, ... Official journal of the American College of Gastroenterology| ACG 110 (5 …, 2015 | 166 | 2015 |
| Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching L De Smedt, S Palmans, D Andel, O Govaere, B Boeckx, D Smeets, ... British journal of cancer 116 (1), 58-65, 2017 | 159 | 2017 |
